Evidence map›Paper›PMID 18782877›Full record

ArticleThe Journal of clinical endocrinology and metabolism2008

Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop.

P Cohen, A D Rogol, C L Deal, P Saenger, E O Reiter, J L Ross, S D Chernausek, M O Savage, J M Wit, 2007 ISS Consensus Workshop participants

Registry-linked trialOpen access · bronzeAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01237041 (Free Fatty Acids, Body Weight, and Growth Hormone Secretion in Children), which is not on this map. Cited by 280 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
280citing papers in PubMed, 8 pooled it
20.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01237041 phase1 / phase2terminatedstarted 2011, after this paper: background citation

Free Fatty Acids, Body Weight, and Growth Hormone Secretion in Children

Ran2011Enrolled37Registered outcomes4Posted comparisons4ConditionsGrowth Hormone Deficiency, Obesity, Short StatureArmsDose-Establishing Study 1 Niacin 250mg, Dose-Establishing Study 1 Niacin 500mg, Dose-Establishing Study 2 Niacin 500mg, Niacin First, Placebo First
PMID 16912138PMID 9024217PMID 27654882other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

280 citing papers in PubMed, 8 syntheses or guidelines pooled it, 724 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Journal of clinical research in pediatric endocrinology · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Healthy short stature.Archives of endocrinology and metabolism · 2026
    Review
  19. Article
  20. Article

220 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 3 countries.

P CohenDepartment of Endocrinology, Mattel Children's Hospital at UCLA, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue MDCC 22-315, Los Angeles, California 90095-1752, USA. hassy@mednet.ucla.edu
A D Rogol
C L Deal
P Saenger
E O Reiter
J L Ross
S D Chernausek
M O Savage
J M Wit
2007 ISS Consensus Workshop participants
Albert Einstein College of Medicine · USBaystate Medical Center · USCentre Hospitalier Universitaire Sainte-Justine · CALeiden University Medical Center · NLMattel Children's Hospital · USThomas Jefferson University · USUniversity of Oklahoma Health Sciences Center · USUniversity of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOur objective was to summarize important advances in the management of children with idiopathic short stature (ISS).

participantsParticipants were 32 invited leaders in the field. EVIDENCE: Evidence was obtained by extensive literature review and from clinical experience. CONSENSUS: Participants reviewed discussion summaries, voted, and reached a majority decision on each document section.

conclusionsISS is defined auxologically by a height below -2 sd score (SDS) without findings of disease as evident by a complete evaluation by a pediatric endocrinologist including stimulated GH levels. Magnetic resonance imaging is not necessary in patients with ISS. ISS may be a risk factor for psychosocial problems, but true psychopathology is rare. In the United States and seven other countries, the regulatory authorities approved GH treatment (at doses up to 53 microg/kg.d) for children shorter than -2.25 SDS, whereas in other countries, lower cutoffs are proposed. Aromatase inhibition increases predicted adult height in males with ISS, but adult-height data are not available. Psychological counseling is worthwhile to consider instead of or as an adjunct to hormone treatment. The predicted height may be inaccurate and is not an absolute criterion for GH treatment decisions. The shorter the child, the more consideration should be given to GH. Successful first-year response to GH treatment includes an increase in height SDS of more than 0.3-0.5. The mean increase in adult height in children with ISS attributable to GH therapy (average duration of 4-7 yr) is 3.5-7.5 cm. Responses are highly variable. IGF-I levels may be helpful in assessing compliance and GH sensitivity; levels that are consistently elevated (>2.5 SDS) should prompt consideration of GH dose reduction. GH therapy for children with ISS has a similar safety profile to other GH indications.

Indexed as

AdultBody HeightBody WeightChildEndocrinologyFemaleGonadotropin-Releasing HormoneGrowth DisordersHumansInsulin-Like Growth Factor IMaleMass ScreeningReference ValuesGonadotropin-Releasing HormoneInsulin-Like Growth Factor I

Identifiers

PMID18782877
OpenAlexW2128962458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.